drugset / Trial / NCT01966120

Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)

NCT01966120

Phase 3 Completed 87 enrolled Biofrontera Bioscience GmbH
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of BF-200 ALA (Ameluz) versus placebo in the field-directed treatment of mild to moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED lamp.

Timeline

Start
2013-10
Primary completion
2014-09
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aminolevulinic Acid Diagnostic / imaging agent Topical

Indications